Tenaya Therapeutics, Inc. is a preclinical stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing a pipeline of disease-modifying therapies developed using its product platforms and capabilities to target defined sub-populations of patients with rare or other prevalent forms of heart disease. The Company is advancing product candidates from three diverse product platforms, such as gene therapy, cellular regeneration, and precision medicine. It is also advancing a diverse pipeline that includes both gene therapies and small molecules. The Company’s capabilities include disease models, capsid engineering, promoters and regulatory elements, drug delivery and manufacturing.
Company Website: https://www.tenayatherapeutics.com